Media Center

Recent News

11/30/18ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesPrinter Friendly Version
11/27/18ACADIA Pharmaceuticals Prices Public Offering of Common StockPrinter Friendly Version
11/26/18ACADIA Pharmaceuticals Announces Proposed Public Offering of Common StockPrinter Friendly Version
11/06/18ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial ResultsPrinter Friendly Version
10/31/18ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)Printer Friendly Version
2018 | 2017 | 2016 | Archive

Company Information

Annual Report


Scientific Publications

Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 383, 533-540 (2014).